Chris has been involved in the research, medical device and biotechnology industry for more than 25 years. Chris was a co-founder of Cytori Therapeutics, Inc./Macropore Biosurgery, Inc. and was CEO/Vice-Chairman of the Board (1996-2014). During his tenure, he brought in more than $400 million and completed transactions with leading device and pharmaceutical companies including GE Healthcare, Olympus Medical, Medtronic, Astellas Pharma, Senko Medical, Kensey Nash, Green Hospital Supply, Lorem Vascular and Mast Biosurgery as well as established a $106 million development contract with BARDA. Chris is an inventor on 96 medical product patent applications. He has presented in more than 100 regenerative medicine, technology and financial conferences and has been an invited lecturer in entrepreneurship and biotechnology at both the Anderson School of Management at UCLA and Rady’s School of Management at UCSD. Chris has a BA from the University of California at San Diego in Economics and an MBA from the University of Phoenix.
New tools have provided improved diagnostics and imaging, more advanced options for physicians to utilize, and targeted therapies, particularly in immunotherapy in the oncology field. Additionally, scientific breakthroughs enable the development of personalized therapies that may dramatically expand the armamentarium of doctors to treat many current medically unaddressed conditions. Looking forward, advanced cell therapies that have been working their way through the development cycle during the last 15 to 20 years are now entering late-stage pre-approval trials. It is this new class of biologic therapy that has the potential to address many of the most significant chronic and complex unmet conditions in healthcare today.12 July 2022